At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed triple-negative breast cancer: ER <5%, PR <5%, HER2 negative per 2020 ASCO/CAP guidelines
- ✓AJCC 8 anatomic stage either T2-T4 N0 M0 or T1-T3 N1-2 M0
- ✓Breast and axillary imaging with mammogram and/or ultrasound and/or MRI within 49 days prior to randomization
- ✓Bilateral invasive breast cancer eligible if both ER-negative, PR-negative, HER2-negative and meet other criteria
- ✕T4/N+, any N3, or inflammatory breast cancer
- ✕Metastatic disease (M1)
- ✕Current or anticipated use of other investigational agents while participating in study
- ✕History of allergic reactions to compounds of similar chemical or biologic composition as study agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
In Brief
A Phase 3 clinical trial evaluating Biospecimen Collection, Carboplatin, and 8 other interventions for Anatomic Stage I Breast Cancer AJCC v8 and 4 related conditions. Currently recruiting, targeting 2,400 participants across 963 sites in 3 countries.
Signals
Detailed Summary
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Study Details
Timeline
Interventions
Undergo collection of blood samples
Given IV
Given IV
Given IV
Given IV
Given IV
Given IV
Ancillary studies
Ancillary studies
Undergo surgery